ShortedShorted

NEUREN PHARMACEUT. ORDINARY (NEU) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens

Highlights Neuren Pharmaceuticals continues advancing its rare neurological disease pipeline while attracting renewed market attention. Progress across commercial licensing and late-stage clinical development remains central to the company's long-term strategy. Investors continue monitoring regulatory milestones, clinical trials and future commercial opportunities. Neuren Pharmaceuticals continues advancing its rare disease pipeline as clinical development, li...

Continue reading
Kalkine
Neutral
just now

ASX 200 Set for Monday Focus: Will Neuren (ASX:NEU) and Gold Stocks Lead the Market?

Highlights The Australian share market is expected to begin the week on a positive note despite mixed overseas trading. Commodity prices, broker updates and dividend adjustments are likely to influence early market activity. Gold miners, energy companies and several dividend-paying shares remain closely watched. The Australian share market is preparing for another active trading session after ending last week with modest gains. Investors will be watching globa...

Continue reading
Kalkine
Positive
just now

NEU (ASX:NEU) DAYBUE Royalties Lift Growth as Sales Rise

Highlights NEU (ASX:NEU) reports around growth in net sales and royalty income, driven by DAYBUE traction. Commercial partner expansion continues to support Rett syndrome treatment uptake. Market attention builds around biotech earnings visibility within the [ASX 200] healthcare sector. NEU (ASX:NEU) continues to grow royalty income from DAYBUE, with rising sales reinforcing its position as a key biotech name in the ASX healthcare sector. Australian healthcare stocks continue to attract...

Continue reading
Kalkine
Neutral
just now

Why Is ASX:NEU Waiting on Europe Daybue Decision Shock?

Highlights Neuren Pharmaceuticals (ASX:NEU) is in focus as its partner awaits a key European regulatory decision on Daybue. Strong North American uptake of the therapy continues to underpin royalty-linked revenue expectations. The outcome could reshape the commercial pathway for Rett syndrome treatment expansion. Neuren Pharmaceuticals is in focus as a European decision on Daybue approaches, with North American success underpinning its rare disease growth narrative and global expansion ...

Continue reading